NCNA
NASD NuCana plc Sponsored ADR$1.09 ↓ -0.05 (-4.34%) Trading Down from the previous close of $1.14
- YTD change
- -69.71%
- vs 20-day SMA
- -13.49%
- vs 200-day SMA
- -44.36%
Price ranges
Price & Performance
-0.76 (-40.00%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $160,000.00
- NCNA is down 70% since the beginning of the year
- NCNA is down 82% over the past 12 months
- NCNA is down 20% over the past 1 month
- 2% of all NCNA investors are betting against NCNA
NCNA reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -80.7%.
- Previous minute
- +$0.00
- Last hour
- +$0.02
- Last 5 days
- -19.22%
- vs 8-day SMA
- -7.19%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.